BCL2 and B-cell chronic lymphocytic leukemia: Standard frontline treatment for CLL (if indicated) often involves either Bruton's tyrosine kinase inhibitors (e.g., ibrutinib, acalabrutinib) or BCL-2 inhibitors (venetoclax) ± anti-CD20 antibodies, depending on risk factors [9].